Anavex Life Sciences Corp (AVXL)

[seventhwave]

So are you dissing A2-73 for it's inability to maintain or increase these cognitive measures. While there may be 5-10% super-responders, expecting it across the tested population an unrealistic expectation that no one on this board harbors.
The A2-73 p2b trial *WILL* show an identifiable differentiation. The question is one of magnitude of differentiation and statistical significance.
Remember, the bar for success is super low as nothing really works currently.
Yes, a lower degree of demonstrated differentiation will result in low gains in SP initially, its safety will ensure it will be the go-to solution for all globally and SP gains will follow prescription growth to our desired SP potential.